Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.69
ACUR's Cash-to-Debt is ranked lower than
68% of the 733 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. ACUR: 0.69 )
Ranked among companies with meaningful Cash-to-Debt only.
ACUR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.61 Max: No Debt
Current: 0.69
Equity-to-Asset -0.06
ACUR's Equity-to-Asset is ranked lower than
97% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. ACUR: -0.06 )
Ranked among companies with meaningful Equity-to-Asset only.
ACUR' s Equity-to-Asset Range Over the Past 10 Years
Min: -7.86  Med: -0.61 Max: 0.97
Current: -0.06
-7.86
0.97
Piotroski F-Score: 2
Altman Z-Score: -70.75
Beneish M-Score: -3.01
WACC vs ROIC
16.22%
-525.71%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -266.31
ACUR's Operating Margin % is ranked lower than
91% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.19 vs. ACUR: -266.31 )
Ranked among companies with meaningful Operating Margin % only.
ACUR' s Operating Margin % Range Over the Past 10 Years
Min: -11455.28  Med: -214.32 Max: 51.47
Current: -266.31
-11455.28
51.47
Net Margin % -291.24
ACUR's Net Margin % is ranked lower than
91% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. ACUR: -291.24 )
Ranked among companies with meaningful Net Margin % only.
ACUR' s Net Margin % Range Over the Past 10 Years
Min: -11301.63  Med: -225.57 Max: 50.74
Current: -291.24
-11301.63
50.74
ROE % -218.36
ACUR's ROE % is ranked lower than
97% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. ACUR: -218.36 )
Ranked among companies with meaningful ROE % only.
ACUR' s ROE % Range Over the Past 10 Years
Min: -218.36  Med: -47.07 Max: 51.89
Current: -218.36
-218.36
51.89
ROA % -72.04
ACUR's ROA % is ranked lower than
93% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. ACUR: -72.04 )
Ranked among companies with meaningful ROA % only.
ACUR' s ROA % Range Over the Past 10 Years
Min: -349.87  Med: -36.27 Max: 33.14
Current: -72.04
-349.87
33.14
ROC (Joel Greenblatt) % -875.17
ACUR's ROC (Joel Greenblatt) % is ranked lower than
90% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.39 vs. ACUR: -875.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACUR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1226.13  Med: -945.65 Max: 1628.06
Current: -875.17
-1226.13
1628.06
3-Year EBITDA Growth Rate -31.40
ACUR's 3-Year EBITDA Growth Rate is ranked lower than
93% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. ACUR: -31.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ACUR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -60.2  Med: -13.4 Max: 50.5
Current: -31.4
-60.2
50.5
3-Year EPS without NRI Growth Rate -22.80
ACUR's 3-Year EPS without NRI Growth Rate is ranked lower than
84% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. ACUR: -22.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACUR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -84.9  Med: -8.8 Max: 56.2
Current: -22.8
-84.9
56.2
GuruFocus has detected 1 Warning Sign with Acura Pharmaceuticals Inc $ACUR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ACUR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ACUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:RSPI, OTCPK:PUFXF, NAS:DCTH, OTCPK:EMMBF, OTCPK:ADMD, OTCPK:NRXCF, OTCPK:YBAO, OTCPK:ULUR, OTCPK:ICCLF, OTCPK:BLONF, OTCPK:AQSZF, AMEX:IGC, OTCPK:RLMD, OTCPK:PARNF, OTCPK:MJTK, OTCPK:CYIG, OTCPK:PVCT, OTCPK:AOLS, OTCPK:TRLPF, OTCPK:PTLF » details
Traded in other countries:HD4B.Germany,
Acura Pharmaceuticals Inc is a pharmaceutical company. It is engaged in the research, development & manufacture of product to address medication abuse & misuse, utilizing the Company's proprietary, tamper-resistant AVERSION & IMPEDE technology platforms.

Acura Pharmaceuticals Inc is a specialty pharmaceutical company engaged in the research, development and commercialization of products intended to address medication abuse and misuse, utilizing its proprietary Aversion and Impede Technologies. The Company has discovered and developed two proprietary technologies; Aversion Technology and Impede Technology. Its Aversion Technology is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules intended to address some common methods of product tampering associated with opioid abuse. Pfizer Inc.s Oxecta or oxycodone HCl tablets CII is the first approved and marketed product utilizing Aversion and is commercialized under its license agreement with a subsidiary of Pfizer, or the Pfizer Agreement. The Company has also developed its Impede Technology which is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. It has 7 additional opioid products utilizing Aversion in various stages of development. It also launched Nexafed commercially in mid-December 2012. The Pfizer Agreement grants Pfizer an exclusive license to develop and commercialize Oxecta. Its potential competitors include, Pain Therapeutics, in collaboration with Pfizer, Purdue Pharma, Atlantic Pharmaceuticals, Egalet Corporation, KemPharm, Shionogi, Nektar Therapeutics, Signature Therapeutics, QRx Pharma, Tris Pharma, Pisgah Labs, and Collegium Pharmaceuticals, Inc. The Company is subject to extensive regulation by the federal government, principally by the FDA under the Federal Food, Drug and Cosmetic Act, or the FD&C Act and to a lesser extent, by state and local governments.

Ratios

vs
industry
vs
history
PS Ratio 1.95
ACUR's PS Ratio is ranked higher than
66% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. ACUR: 1.95 )
Ranked among companies with meaningful PS Ratio only.
ACUR' s PS Ratio Range Over the Past 10 Years
Min: 1.6  Med: 9.31 Max: 1011.11
Current: 1.95
1.6
1011.11
Current Ratio 1.26
ACUR's Current Ratio is ranked lower than
79% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. ACUR: 1.26 )
Ranked among companies with meaningful Current Ratio only.
ACUR' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.58 Max: 68.17
Current: 1.26
0.02
68.17
Quick Ratio 1.16
ACUR's Quick Ratio is ranked lower than
70% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. ACUR: 1.16 )
Ranked among companies with meaningful Quick Ratio only.
ACUR' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 1.36 Max: 68.17
Current: 1.16
0.01
68.17
Days Inventory 205.68
ACUR's Days Inventory is ranked lower than
83% of the 642 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. ACUR: 205.68 )
Ranked among companies with meaningful Days Inventory only.
ACUR' s Days Inventory Range Over the Past 10 Years
Min: 161.36  Med: 446.2 Max: 752.41
Current: 205.68
161.36
752.41
Days Sales Outstanding 18.26
ACUR's Days Sales Outstanding is ranked higher than
92% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. ACUR: 18.26 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACUR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.73  Med: 31.49 Max: 575.69
Current: 18.26
2.73
575.69
Days Payable 357.90
ACUR's Days Payable is ranked higher than
97% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.13 vs. ACUR: 357.90 )
Ranked among companies with meaningful Days Payable only.
ACUR' s Days Payable Range Over the Past 10 Years
Min: 61.2  Med: 348.92 Max: 877.28
Current: 357.9
61.2
877.28

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.80
ACUR's 3-Year Average Share Buyback Ratio is ranked lower than
66% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. ACUR: -8.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACUR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -166.7  Med: -8.8 Max: -0.9
Current: -8.8
-166.7
-0.9

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.21
ACUR's Price-to-Median-PS-Value is ranked higher than
98% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. ACUR: 0.21 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACUR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 0.55 Max: 118.75
Current: 0.21
0.05
118.75
Earnings Yield (Greenblatt) % -98.32
ACUR's Earnings Yield (Greenblatt) % is ranked lower than
98% of the 1021 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.62 vs. ACUR: -98.32 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACUR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -105.2  Med: 8.7 Max: 48.2
Current: -98.32
-105.2
48.2

More Statistics

Revenue (TTM) (Mil) $3.38
EPS (TTM) $ -0.82
Beta2.32
Short Percentage of Float1.20%
52-Week Range $0.46 - 3.52
Shares Outstanding (Mil)11.83

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1 1 32 87
EPS ($) -0.92 -0.44 0.37 0.84
EPS without NRI ($) -0.92 -0.44 0.37 0.84
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ACUR

Headlines

Articles On GuruFocus.com
What to Watch for: November 3-7 Nov 04 2014 
Acura Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 02 2010 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Jul 29 2010 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 26 2009 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Jul 30 2009 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) May 01 2009 

More From Other Websites
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... Mar 17 2017
Acura Pharmaceuticals and MainPointe Pharmaceuticals Announce Deal for Nexafed® Products Mar 17 2017
ACURA PHARMACEUTICALS, INC Financials Feb 28 2017
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers Feb 24 2017
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Feb 15 2017
Acura Pharmaceuticals Common Stock To Trade On The OTCQB Market Feb 15 2017
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Jan 27 2017
Implied Volatility Surging for Acura (ACUR) Stock Options Jan 10 2017
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Other Events Jan 03 2017
Acura Pharmaceuticals Exploring Strategic Alternatives Jan 03 2017
Acura Pharmaceuticals Exploring Strategic Alternatives Jan 03 2017
ETFs with exposure to Acura Pharmaceuticals, Inc. : December 23, 2016 Dec 23 2016
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Other Events Dec 14 2016
Acura Pharmaceutical Provides Development Update on its LIMITx(TM) Technology Dec 14 2016
ETFs with exposure to Acura Pharmaceuticals, Inc. : December 7, 2016 Dec 07 2016
Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016 Nov 18 2016
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 15 2016
ACURA PHARMACEUTICALS, INC Files SEC form 10-Q, Quarterly Report Nov 14 2016
Acura Pharmaceuticals Announces Third Quarter 2016 Financial Results Nov 14 2016
Acura Pharmaceuticals Announces Third Quarter 2016 Financial Results Nov 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)